Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care

Cancer remains a major health concern globally. Immune checkpoint inhibitors (ICIs) target co-inhibitory immune checkpoint molecules and have received approval for treating malignancies like melanoma and non-small cell lung cancer. While CTLA-4 and PD-1/PD-L1 are extensively researched, additional t...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yao Xiao, Zi-Zhan Li, Nian-Nian Zhong, Lei-Ming Cao, Bing Liu, Lin-Lin Bu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-12-01
Rangatū:	Translational Oncology
Ngā marau:	Co-inhibitory immune checkpoint Immune checkpoint inhibitor Biomarker Drug delivery system Immunotherapy
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1936523323001808
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!